Why the study?
Does an elevated D-dimer predict incident VTE, recurrent VTE, and mortality in medically ill subjects?
Does an elevated D-dimer predict incident VTE, recurrent VTE, and mortality in medically ill subjects?
Elevated D-dimer identifies a high-risk subgroup of medically ill patients who may benefit from prospective evaluation of antithrombotic therapy.
May identify high-risk medically ill patients for antithrombotic trials; leaves open routine adoption pending randomized data.
D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated D-dimer with adverse outcomes has received far less emphasis. An elevated D-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated D-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the D-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.
No takes yet. Share an insight, caveat, or question.
Halaby et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: